Las Vegas, NV -- (SBWIRE) -- 12/10/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is on: Polycom Inc (NASDAQ:PLCM), Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Avanir Pharmaceuticals Inc (NASDAQ:AVN), Sarepta Therapeutics Inc(NASDAQ:SRPT)
Polycom Inc (NASDAQ:PLCM) managed to keep its fall at -1.39% on below -normal volume of 1.36M shares. The stock settled at $10.67 after floating in a range of $10.61 to $10.99. Its latest price has reached market capitalization of $1.82 billion. Its 52-week range has been $9 to $11.94. Polycom, Inc. is a provider of unified communications (UC) solutions and a provider of telepresence, video, voice and infrastructure solutions based on open standards. With Polycom RealPresence video and voice solutions, from infrastructure to endpoints, people all over the world can collaborate face-to-face without being in the same physical location.
Has PLCM Found The Bottom and Ready To Move Up? Find Out Here
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) traded down on a volume of 1.37 million, lower than its standard daily volume. Shares have dropped-3.82% to $4.79. Over the last twelve months, the stock has lost/-38.11% and faced a worst price of $3.70. Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development. Its drug candidates are discovered and developed internally, using its chemical compound library and integrated discovery engine.
Has SNTA Found The Bottom And Ready To Gain Momentum? Find Out Here
Avanir Pharmaceuticals Inc (NASDAQ:AVN) settled 1.38% higher at $4.40 on below -normal volume of 1.37M shares during the last trading day. The stock has its 12-month high at $6and 52-week low price was $2.34. It traded in a range of $4.27 to $4.40 during the last trading day. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas.
Why Should Investors Buy AVN After the Recent Fall? Just Go Here and Find Out
In the last trading session, Sarepta Therapeutics Inc(NASDAQ:SRPT) was down on low volume, trading at a volume of 1.35M shares versus its average daily volume of 3.74 million shares. At $17.86, the stock has attained market capitalization of $671.22 million. Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. Its product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100.
Why Should Investors Buy SRPT After the Recent Fall? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)